HDAC1, a novel marker for benign teratomas

Histone deacetylases (HDACs) are attractive chemotherapy targets, owing to their pro-proliferative activities. However, the finding that loss of HDAC1 promotes teratoma malignancy calls for caution in the use of HDAC inhibitors as cancer therapeutics.

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Simboeck, Elisabeth, Di Croce, Luciano
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2010
Konular:
Have You Seen...?
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020642/
https://ncbi.nlm.nih.gov/pubmed/21124297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/emboj.2010.281
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller